Phase II trial of cisplatin and tegafur (Ftorafur) as initial therapy in squamous-cell carcinoma of the head and neck

Am J Clin Oncol. 1990 Aug;13(4):312-4. doi: 10.1097/00000421-199008000-00009.

Abstract

Cisplatin and 5-fluorouracil infusion combination produces a high response rate in squamous-cell carcinoma of the head and neck. Tegafur (Ftorafur) is an analog of 5-fluorouracil, and its oral form is well absorbed. This agent has a moderate toxicity. We report a study to determine the efficacy of the cisplatin (100 mg/m2, day 1) and tegafur (1,000 mg/m2 daily for 21 days) combination. Thirty-nine patients entered the study; 36 were evaluable for response. Overall response was 94%, with a 22% complete response. Toxicity was moderate. We conclude that the cisplatin and tegafur combination is active in untreated patients with head and neck cancer.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / toxicity
  • Carcinoma, Squamous Cell / drug therapy*
  • Cisplatin / administration & dosage*
  • Cisplatin / toxicity
  • Drug Evaluation
  • Female
  • Head and Neck Neoplasms / drug therapy*
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Remission Induction
  • Tegafur / administration & dosage*
  • Tegafur / toxicity

Substances

  • Tegafur
  • Cisplatin